Developer docs
API playgroundTry for free, no card

Search company profiles

Rhythm Biosciences

Full company profile

uuid0005t9o

Namestring
Rhythm Biosciences
Legal namestring
Rhythm Biosciences
Websiteurl
rhythmbio.com
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Rhythm Biosciences Limited (ASX:RHY) is an Australian medical diagnostics technology company that develops and commercializes blood-based tests for the prediction and early detection of cancer. The company operates a dual-product portfolio: ColoSTAT®, a proprietary multiplex immunoassay blood test designed to detect colorectal cancer in symptomatic patients and described as Australia's first such test, and geneType™, a portfolio of personalized predictive tests that combine polygenic risk scores (PRS) with clinical and family history data to forecast individual risk across six cancer types. The geneType portfolio includes the Multi Risk Test (MRT) and the Hereditary Breast and Ovarian Cancer (HBOC) test, the latter of which has received FDA clearance for the US market. The platform rests on a second-generation multiplex alpha immunoassay chemistry for ColoSTAT and a patented PRS framework for geneType, supported by 25 granted patents (plus 9 pending), NATA ISO15189:2022-accredited laboratory operations, and ISO 13485 medical device certification.

The business model combines one-time product revenue from ColoSTAT kit sales with recurring testing services revenue from geneType laboratory operations, supplemented by Australian R&D tax incentives and non-dilutive funding facilities (e.g., an Endpoints Capital loan tranche). Commercialization is executed through a hybrid go-to-market: direct enterprise sales for ColoSTAT paired with channel partnerships — most notably a CancerIQ platform integration reaching 60-65 US health systems, a 4Cyte Pathology collection agreement in Australia, an AGRF partnership for laboratory scale-up, and regional distribution agreements for the UK and Southeast Asia. The company serves three primary segments: healthcare providers and clinicians ordering the tests, large health systems and hospital networks seeking population-level screening tools, and at-risk individuals seeking personalized risk assessment.

Rhythm remains in early commercial launch phase. Its flagship ColoSTAT product commenced commercialization in December 2025 following ISO15189:2022 accreditation, with the first clinical test sale recorded in March 2026. The geneType portfolio was added through an acquisition completed in December 2024, with first commercial sales recorded shortly thereafter and international expansion into Southeast Asia commencing in early 2026. The company maintains wholly-owned subsidiaries in the US (established July 2021) and the UK (established July 2023) to support multi-region growth.

Short descriptiontext

Rhythm Biosciences is an Australian medtech company that develops blood-based cancer diagnostics, including the ColoSTAT colorectal cancer test and the geneType polygenic risk score portfolio, serving clinicians, health systems, and pathology networks across Australia, the US, the UK, and Southeast Asia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
blood-based cancer diagnostics, colorectal cancer screening, polygenic risk assessment, cancer risk prediction, medical diagnostics platform
Industry5 codes
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAFAMAL
Clinical Research & Trial Central Laboratories
NAICS code4 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • Scientific Research and Development Services5417
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Cancer Diagnostics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1ColoSTAT Product Sales
TypeOne Time License
Description

Revenue from sale of ColoSTAT blood test kits for colorectal cancer detection in symptomatic patients. Commercial manufacturing agreement secured for kit production.

rhythmbio.com
2geneType Laboratory Testing Services
TypeSubscription Recurring
Description

Revenue from geneType cancer risk assessment testing services, including polygenic risk score tests for multiple cancer types. Laboratory operations NATA ISO15189 certified.

rhythmbio.com
3Non-Dilutive Funding
TypeLicensing Royalties
Description

Company receives R&D tax incentives from Australian government and non-dilutive funding arrangements such as the Endpoints Capital loan facility.

rhythmbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1ColoSTAT
Description

Blood-based test for the early detection of colorectal cancer in symptomatic patients.

rhythmbio.com
+1 more record
Core offering1 text field

Rhythm Biosciences develops and commercialises proprietary blood-based diagnostic tests for cancer detection and risk assessment. Its flagship product ColoSTAT is a blood test for colorectal cancer detection in symptomatic patients, and the geneType portfolio combines genomic and clinical data into polygenic risk score tests covering multiple cancer types. The company manufactures test kits, operates NATA ISO15189-certified laboratories, and distributes through pathology networks, health system platforms, and international partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 79.5% of geneType Multi Risk Tests provide novel health insights previously unknown to patients
+2 more records
Product overview1 text field

Rhythm Biosciences operates a dual-product portfolio focused on cancer diagnostics. The company's flagship products are ColoSTAT® (a blood-based test for colorectal cancer detection in symptomatic patients) and geneType™ (a world-leading personalised predictive test portfolio combining genomic and clinical information to assess cancer risk across multiple cancer types). geneType™ includes the Multi Risk Test (MRT) that assesses multiple conditions simultaneously, and the Hereditary Breast and Ovarian Cancer (HBOC) test. The company is expanding its proprietary immunoassay technology platform to develop diagnostic tests for additional cancer types including lung, gastric, and breast cancer.

Product and service4 records
1ColoSTAT®
CategoryCancer Diagnostics
Description

Australia's first blood-based test for detection of colorectal (bowel) cancer in symptomatic patients. A proprietary multiplex immunoassay designed to support risk stratification and help clinicians determine which patients may benefit from further investigation such as colonoscopy.

2geneType™ Platform
CategoryCancer Diagnostics
Description

Portfolio of personalised predictive tests combining genomic and clinical information, including family history, to forecast an individual's risk of developing cancer. Provides 5-year and lifetime cancer risk estimates across six cancer types.

3geneType™ Multi Risk Test (MRT)
CategoryCancer Diagnostics
Description

Sub-product within the geneType portfolio that assesses multiple cancer conditions simultaneously using polygenic risk scores combined with clinical and family history data. 79.5% of tests deliver novel health insights previously unknown to patients.

4geneType™ Hereditary Breast and Ovarian Cancer (HBOC) Test
CategoryCancer Diagnostics
Description

Comprehensive screening tool for hereditary breast and ovarian cancer risk assessment, currently available in the US market following FDA clearance.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Southeast Asian Distribution Partner
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-04
Description

Rhythm Biosciences executed a distribution agreement for geneType in the Southeast Asian market, enabling geographic expansion across the region.

rhythmbio.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-17
Description

Rhythm Biosciences entered into a ColoSTAT services agreement with 4Cyte Pathology for specimen collection and testing services. 4Cyte Pathology operates an expanding network of collection sites supporting the commercial rollout of ColoSTAT across Australia.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-29
Description

Rhythm Biosciences established a strategic partnership with AGRF to accelerate commercial scale-up of the geneType service. AGRF provides laboratory and genomic services supporting expanded testing capacity and operational scaling.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-28
Description

CancerIQ is a US digital healthcare platform that integrated Rhythm Biosciences' geneType cancer risk assessment test into its platform. This partnership expands diagnostic options across CancerIQ's network of over 60 health systems in the United States, enhancing risk prediction by incorporating polygenic risk scores and clinical data for six cancer types. The integration enables healthcare providers to order tests more efficiently through established clinical workflows, expanding patient access to predictive cancer diagnostics.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-12-22
Description

datma and Rhythm Biosciences announced an exploratory collaboration to evaluate how datma's federated real-world data platform (datma.FED) could support Rhythm's cancer risk prediction technology development. The collaboration aims to assess the contribution of longitudinal, de-identified clinical data to support clinical utility and health economic modelling of Rhythm's geneType risk assessment portfolio, potentially enhancing commercialization and clinical validation of genomic-integrated cancer diagnostics.

6Catch Bio
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-12-09
Description

Rhythm Biosciences entered a US marketing partnership with Catch Bio to support commercial adoption and marketing efforts in the United States market.

rhythmbio.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-07-24
Description

Collaboration with Memorial Sloan Kettering Cancer Center, a world-renowned cancer research and treatment institution, for cancer diagnostics development.

8LINK Medical Solutions
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-05-24
Description

UK strategic partnership with LINK Medical Solutions for UK market entry and commercialization support. LINK Medical Solutions provides medical device commercialization expertise in the UK market.

rhythmbio.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US liquid-biopsy company offering blood-based cancer screening (Shield for CRC) and comprehensive genomic profiling. Direct blood-based CRC competitor and overlapping oncology liquid-biopsy peer with substantially larger capital base.

TypeBroad incumbent
Description

US cell-free DNA testing company with oncology screening (Signatera MRD) and reproductive health offerings. Comparable as a blood-based cancer diagnostics peer with established US commercial infrastructure, though core franchise is MRD rather than screening.

TypeEmerging player
Description

Privately held US multiomics blood-based cancer screening company focused on CRC with an emerging pipeline into other cancers. Closely comparable in modality and product category but at a different development and capital stage.

TypeDirect peer
Description

US-listed developer of Cologuard, the leading non-invasive stool-DNA test for colorectal cancer screening. Direct competitor in non-invasive CRC detection; however, blood-based vs stool-based modalities differ and Exact Sciences has substantially greater scale and US reimbursement coverage.

TypeEmerging player
Description

US cancer genomics company focused on minimal residual disease detection and immunotherapy selection. Comparable as a clinical genomics peer operating at similar scale, though its core focus is post-diagnosis rather than screening or risk prediction.

TypeEmerging player
Description

Privately held developer of blood-based colorectal cancer screening tests. Closely comparable modality (blood-based CRC detection) and competitor in the same clinical category.

TypeRegional player
Description

ASX-listed global pathology and radiology provider with major Australian clinical laboratory operations. Comparable Australian-region pathology infrastructure and a likely channel partner or competitive constraint for ColoSTAT specimen logistics.

TypeBroad incumbent
Description

US established genetic testing company with hereditary cancer (BRACAnalysis) and other risk-prediction products. Direct comparable on the geneType-style hereditary cancer and polygenic risk offering, with established US clinical channel.

TypeRegional player
Description

Australian operator of pathology and diagnostic services including QML, Dorevitch and Laverty pathology networks. Comparable as a regional Australian diagnostics and pathology services incumbent and potential distribution channel for ColoSTAT.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rhythm Biosciences

Cancer Diagnosticsrhythmbio.com

Rhythm Biosciences is an Australian medtech company that develops blood-based cancer diagnostics, including the ColoSTAT colorectal cancer test and the geneType polygenic risk score portfolio, serving clinicians, health systems, and pathology networks across Australia, the US, the UK, and Southeast Asia.

What Rhythm Biosciences does

Rhythm Biosciences Limited (ASX:RHY) is an Australian medical diagnostics technology company that develops and commercializes blood-based tests for the prediction and early detection of cancer. The company operates a dual-product portfolio: ColoSTAT®, a proprietary multiplex immunoassay blood test designed to detect colorectal cancer in symptomatic patients and described as Australia's first such test, and geneType™, a portfolio of personalized predictive tests that combine polygenic risk scores (PRS) with clinical and family history data to forecast individual risk across six cancer types. The geneType portfolio includes the Multi Risk Test (MRT) and the Hereditary Breast and Ovarian Cancer (HBOC) test, the latter of which has received FDA clearance for the US market. The platform rests on a second-generation multiplex alpha immunoassay chemistry for ColoSTAT and a patented PRS framework for geneType, supported by 25 granted patents (plus 9 pending), NATA ISO15189:2022-accredited laboratory operations, and ISO 13485 medical device certification.

The business model combines one-time product revenue from ColoSTAT kit sales with recurring testing services revenue from geneType laboratory operations, supplemented by Australian R&D tax incentives and non-dilutive funding facilities (e.g., an Endpoints Capital loan tranche). Commercialization is executed through a hybrid go-to-market: direct enterprise sales for ColoSTAT paired with channel partnerships — most notably a CancerIQ platform integration reaching 60-65 US health systems, a 4Cyte Pathology collection agreement in Australia, an AGRF partnership for laboratory scale-up, and regional distribution agreements for the UK and Southeast Asia. The company serves three primary segments: healthcare providers and clinicians ordering the tests, large health systems and hospital networks seeking population-level screening tools, and at-risk individuals seeking personalized risk assessment.

Rhythm remains in early commercial launch phase. Its flagship ColoSTAT product commenced commercialization in December 2025 following ISO15189:2022 accreditation, with the first clinical test sale recorded in March 2026. The geneType portfolio was added through an acquisition completed in December 2024, with first commercial sales recorded shortly thereafter and international expansion into Southeast Asia commencing in early 2026. The company maintains wholly-owned subsidiaries in the US (established July 2021) and the UK (established July 2023) to support multi-region growth.

Rhythm Biosciences firmographics

Firmographics
Name
Rhythm Biosciences
Legal name
Rhythm Biosciences
Website
https://rhythmbio.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Rhythm Biosciences is an Australian medtech company that develops blood-based cancer diagnostics, including the ColoSTAT colorectal cancer test and the geneType polygenic risk score portfolio, serving clinicians, health systems, and pathology networks across Australia, the US, the UK, and Southeast Asia.
Ownership category
akta.pro rank

Rhythm Biosciences industry classification

Industry
Product category
Cancer Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAFAMAL
Clinical Research & Trial Central Laboratories

Keywords

  • Blood-based cancer diagnostics
  • Colorectal cancer screening
  • Polygenic risk assessment
  • Cancer risk prediction
  • Medical diagnostics platform

Where Rhythm Biosciences is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Rhythm Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. ColoSTAT Product Sales: Revenue from sale of ColoSTAT blood test kits for colorectal cancer detection in symptomatic patients. Commercial manufacturing agreement secured for kit production.
  2. geneType Laboratory Testing Services: Revenue from geneType cancer risk assessment testing services, including polygenic risk score tests for multiple cancer types. Laboratory operations NATA ISO15189 certified.
  3. Non-Dilutive Funding: Company receives R&D tax incentives from Australian government and non-dilutive funding arrangements such as the Endpoints Capital loan facility.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Rhythm Biosciences product offering

Product offering

Core offering

Rhythm Biosciences develops and commercialises proprietary blood-based diagnostic tests for cancer detection and risk assessment. Its flagship product ColoSTAT is a blood test for colorectal cancer detection in symptomatic patients, and the geneType portfolio combines genomic and clinical data into polygenic risk score tests covering multiple cancer types. The company manufactures test kits, operates NATA ISO15189-certified laboratories, and distributes through pathology networks, health system platforms, and international partners.

Product overview

Rhythm Biosciences operates a dual-product portfolio focused on cancer diagnostics. The company's flagship products are ColoSTAT® (a blood-based test for colorectal cancer detection in symptomatic patients) and geneType™ (a world-leading personalised predictive test portfolio combining genomic and clinical information to assess cancer risk across multiple cancer types). geneType™ includes the Multi Risk Test (MRT) that assesses multiple conditions simultaneously, and the Hereditary Breast and Ovarian Cancer (HBOC) test. The company is expanding its proprietary immunoassay technology platform to develop diagnostic tests for additional cancer types including lung, gastric, and breast cancer.

Differentiator

Problem solved

Functional benefit

Brands

  • ColoSTAT: Blood-based test for the early detection of colorectal cancer in symptomatic patients.
  • geneType

Products and services

  • ColoSTAT® Australia's first blood-based test for detection of colorectal (bowel) cancer in symptomatic patients. A proprietary multiplex immunoassay designed to support risk stratification and help clinicians determine which patients may benefit from further investigation such as colonoscopy.
  • geneType™ Platform Portfolio of personalised predictive tests combining genomic and clinical information, including family history, to forecast an individual's risk of developing cancer. Provides 5-year and lifetime cancer risk estimates across six cancer types.
  • geneType™ Multi Risk Test (MRT) Sub-product within the geneType portfolio that assesses multiple cancer conditions simultaneously using polygenic risk scores combined with clinical and family history data. 79.5% of tests deliver novel health insights previously unknown to patients.
  • geneType™ Hereditary Breast and Ovarian Cancer (HBOC) Test Comprehensive screening tool for hereditary breast and ovarian cancer risk assessment, currently available in the US market following FDA clearance.

Quantifiable outcome

  • 79.5% of geneType Multi Risk Tests provide novel health insights previously unknown to patients
  • +2 more outcomes

Companies that use Rhythm Biosciences

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Rhythm Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Rhythm Biosciences partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor and core.

  • Southeast Asian Distribution PartnerminorChannel Partner/ Reseller/ Distributor · 4 March 2026Rhythm Biosciences executed a distribution agreement for geneType in the Southeast Asian market, enabling geographic expansion across the region.
  • 4Cyte PathologycoreChannel Partner/ Reseller/ Distributor · 17 February 2026Rhythm Biosciences entered into a ColoSTAT services agreement with 4Cyte Pathology for specimen collection and testing services. 4Cyte Pathology operates an expanding network of collection sites supporting the commercial rollout of ColoSTAT across Australia.
  • AGRF (Australian Genome Research Facility)coreStrategic or Co-development Partner · 29 January 2026Rhythm Biosciences established a strategic partnership with AGRF to accelerate commercial scale-up of the geneType service. AGRF provides laboratory and genomic services supporting expanded testing capacity and operational scaling.
  • CancerIQcoreChannel Partner/ Reseller/ Distributor · 28 January 2026CancerIQ is a US digital healthcare platform that integrated Rhythm Biosciences' geneType cancer risk assessment test into its platform. This partnership expands diagnostic options across CancerIQ's network of over 60 health systems in the United States, enhancing risk prediction by incorporating polygenic risk scores and clinical data for six cancer types. The integration enables healthcare providers to order tests more efficiently through established clinical workflows, expanding patient access to predictive cancer diagnostics.
  • datmaminorStrategic or Co-development Partner · 22 December 2025datma and Rhythm Biosciences announced an exploratory collaboration to evaluate how datma's federated real-world data platform (datma.FED) could support Rhythm's cancer risk prediction technology development. The collaboration aims to assess the contribution of longitudinal, de-identified clinical data to support clinical utility and health economic modelling of Rhythm's geneType risk assessment portfolio, potentially enhancing commercialization and clinical validation of genomic-integrated cancer diagnostics.
  • Catch BiominorGTM or Marketing Partner · 9 December 2025Rhythm Biosciences entered a US marketing partnership with Catch Bio to support commercial adoption and marketing efforts in the United States market.
  • Memorial Sloan Kettering (MSK)minorStrategic or Co-development Partner · 24 July 2025Collaboration with Memorial Sloan Kettering Cancer Center, a world-renowned cancer research and treatment institution, for cancer diagnostics development.
  • LINK Medical SolutionsminorChannel Partner/ Reseller/ Distributor · 24 May 2023UK strategic partnership with LINK Medical Solutions for UK market entry and commercialization support. LINK Medical Solutions provides medical device commercialization expertise in the UK market.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Rhythm Biosciences competitors and assessment

Company assessment

Others

Direct peers

  • Guardant Health: US liquid-biopsy company offering blood-based cancer screening (Shield for CRC) and comprehensive genomic profiling. Direct blood-based CRC competitor and overlapping oncology liquid-biopsy peer with substantially larger capital base.
  • Exact Sciences: US-listed developer of Cologuard, the leading non-invasive stool-DNA test for colorectal cancer screening. Direct competitor in non-invasive CRC detection; however, blood-based vs stool-based modalities differ and Exact Sciences has substantially greater scale and US reimbursement coverage.

Broad incumbents

  • Natera: US cell-free DNA testing company with oncology screening (Signatera MRD) and reproductive health offerings. Comparable as a blood-based cancer diagnostics peer with established US commercial infrastructure, though core franchise is MRD rather than screening.
  • Myriad Genetics: US established genetic testing company with hereditary cancer (BRACAnalysis) and other risk-prediction products. Direct comparable on the geneType-style hereditary cancer and polygenic risk offering, with established US clinical channel.

Emerging players

  • Freenome: Privately held US multiomics blood-based cancer screening company focused on CRC with an emerging pipeline into other cancers. Closely comparable in modality and product category but at a different development and capital stage.
  • Personalis: US cancer genomics company focused on minimal residual disease detection and immunotherapy selection. Comparable as a clinical genomics peer operating at similar scale, though its core focus is post-diagnosis rather than screening or risk prediction.
  • Universal Diagnostics: Privately held developer of blood-based colorectal cancer screening tests. Closely comparable modality (blood-based CRC detection) and competitor in the same clinical category.

Regional players

  • Sonic Healthcare: ASX-listed global pathology and radiology provider with major Australian clinical laboratory operations. Comparable Australian-region pathology infrastructure and a likely channel partner or competitive constraint for ColoSTAT specimen logistics.
  • Healius (formerly Primary Health Care): Australian operator of pathology and diagnostic services including QML, Dorevitch and Laverty pathology networks. Comparable as a regional Australian diagnostics and pathology services incumbent and potential distribution channel for ColoSTAT.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Rhythm Biosciences social profiles

Digital presence

Rhythm Biosciences compliance and trust

Trust signal

Compliance4 records

Rhythm Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rhythm Biosciences leadership team

Management profile

Number of profiles

Profiles7 records

Rhythm Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Rhythm Biosciences funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rhythm Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rhythm Biosciences

What does Rhythm Biosciences do?

Rhythm Biosciences develops and commercialises proprietary blood-based diagnostic tests for cancer detection and risk assessment. Its flagship product ColoSTAT is a blood test for colorectal cancer detection in symptomatic patients, and the geneType portfolio combines genomic and clinical data into polygenic risk score tests covering multiple cancer types. The company manufactures test kits, operates NATA ISO15189-certified laboratories, and distributes through pathology networks, health system platforms, and international partners.

Is Rhythm Biosciences a public or private company?

Rhythm Biosciences is a public company. It is classified as public and is currently operating.

When was Rhythm Biosciences founded?

Rhythm Biosciences was founded in 2019. It employs 11 to 50 people.

Where is Rhythm Biosciences based?

Rhythm Biosciences is headquartered in Melbourne, Australia, in the Oceania region.

How does Rhythm Biosciences make money?

Three revenue lines are on record. ColoSTAT Product Sales are the primary driver. The others are geneType Laboratory Testing Services and non-Dilutive Funding.

Who are Rhythm Biosciences's main competitors?

Genomic Health (Exact Sciences subsidiary) is listed as an others. Direct peers are Guardant Health and Exact Sciences. Broad incumbents are Natera and Myriad Genetics. Emerging players are Freenome, Personalis and Universal Diagnostics. Regional players are Sonic Healthcare and Healius (formerly Primary Health Care).

Does Rhythm Biosciences have an API?

No public API is recorded for Rhythm Biosciences.

What industry is Rhythm Biosciences in?

Rhythm Biosciences's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournCancerIQ Expands Diagnostic Network with Addition of geneType™ PRS Test from Rhythm BiosciencesCancerIQ has integrated the geneType™ cancer risk assessment test from Rhythm Biosciences into its platform, expanding diagnostic options across its network of over 60 health systems. The test enhances risk prediction by incorporating polygenic risk scores and clinical data for six cancer types.PR NewswireCancerIQ Expands Diagnostic Network with Addition of geneType™ PRS Test from Rhythm BiosciencesCancerIQ announced that Rhythm Biosciences' geneType™ Cancer Risk Assessment test is now available on its precision health platform, expanding diagnostic tools across its network of 60+ health systems in the US. The geneType™ test combines polygenic risk scores with clinical and family history to provide 5-year and lifetime cancer risk estimates across six cancer types. The partnership integrates the test into existing clinical workflows, enabling providers to order the assessment directly through CancerIQ's EHR-integrated platform.Kalkine MediaRhythm Biosciences (ASX:RHY) Tracks All Ordinaries Innovation TrendsRhythm Biosciences develops diagnostic testing platforms for detecting disease markers within clinical and laboratory environments. The article describes its focus on healthcare solutions, regulatory compliance, and laboratory integration.Daily TelegraphRhythm Biosciences partners with CancerIQRhythm Biosciences has announced a strategic partnership with US digital healthcare platform CancerIQ to integrate its geneType cancer risk assessment into CancerIQ's workflow, enabling healthcare providers to order tests more efficiently. The partnership aims to expand test volumes, accelerate revenue growth, and strengthen Rhythm's presence in the US market by embedding its technology in a platform already used by over 65 US health systems. The collaboration supports broader adoption of genomic risk assessment tools and scalable deployment across large healthcare networks in the United States.The AustralianRhythm Biosciences partners with CancerIQRhythm Biosciences formed a strategic partnership with US digital healthcare platform CancerIQ to integrate its geneType cancer risk assessment into CancerIQ's workflow. This integration aims to enhance clinical efficiency and support scalable commercialization across US healthcare providers, expanding patient access to predictive cancer diagnostics.The AustralianRhythm Biosciences teams up with US-based datmaRhythm Biosciences (ASX:RHY) has entered an exploratory collaboration with US-based datma to evaluate how datma's federated data platform (datma.FED) could support the development and commercialization of Rhythm's genomic-integrated cancer risk prediction tools, including its geneType platform. The partnership aims to address data fragmentation and privacy barriers by enabling secure, privacy-preserving access to de-identified real-world clinical data across multiple healthcare organizations. datma CEO Noah Nasser and Rhythm Biosciences director of clinical affairs Dr Erika Spaeth provided statements on the collaboration's potential to advance genomic-integrated risk prediction for cancer diagnostics.PR Newswiredatma and Rhythm Biosciences Announce Collaboration to Apply Federated Real-World Data to Genomic Diagnostic Developmentdatma and Rhythm Biosciences announced an exploratory collaboration to evaluate how datma's federated real-world data platform, datma.FED, can support the development of Rhythm's genomic-integrated cancer risk prediction portfolio. The partnership aims to address data fragmentation and privacy constraints by enabling secure access to de-identified clinical data for evidence generation and health economic modeling. Subject to successful validation, the companies will discuss further commercial agreements.Streetinsiderdatma and Rhythm Biosciences Announce Collaboration to Apply Federated Real-World Data to Genomic Diagnostic Developmentdatma and Rhythm Biosciences Ltd have announced an exploratory collaboration to evaluate how datma.FED, a federated real-world data platform, could support and accelerate the commercialization of Rhythm's genomic-integrated cancer risk prediction portfolio, geneType™. The collaboration will assess how longitudinal, de-identified clinical data accessible via datma.FED may contribute to continued development of Rhythm's risk scoring technologies and support clinical utility evidence generation. Subject to successful validation, further partnership discussions will ensue, including potentially utilizing geneType™ technology within the datma.FED platform.MarketScreenerRhythm Biosciences says Gavin Fox-Smith appointed chairRhythm Biosciences Limited announced the appointment of Gavin Fox-Smith as chairman. The company is an Australian medical diagnostics firm specializing in blood tests for early cancer detection.